Verweij J - Search Results

1

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Smorenburg CH, et al. Among authors: verweij j. J Clin Oncol. 2003 Jan 15;21(2):197-202. doi: 10.1200/JCO.2003.01.058. J Clin Oncol. 2003. PMID: 12525510 Clinical Trial.

2

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. Among authors: verweij j. J Clin Oncol. 2002 Jan 1;20(1):81-7. doi: 10.1200/JCO.2002.20.1.81. J Clin Oncol. 2002. PMID: 11773157

3

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions.

Gelderblom H, Mross K, ten Tije AJ, Behringer D, Mielke S, van Zomeren DM, Verweij J, Sparreboom A. Gelderblom H, et al. Among authors: verweij j. J Clin Oncol. 2002 Jan 15;20(2):574-81. doi: 10.1200/JCO.2002.20.2.574. J Clin Oncol. 2002. PMID: 11786588 Clinical Trial.

4

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

Kehrer DF, Bos AM, Verweij J, Groen HJ, Loos WJ, Sparreboom A, de Jonge MJ, Hamilton M, Cameron T, de Vries EG. Kehrer DF, et al. Among authors: verweij j. J Clin Oncol. 2002 Mar 1;20(5):1222-31. doi: 10.1200/JCO.2002.20.5.1222. J Clin Oncol. 2002. PMID: 11870164 Clinical Trial.

5

Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.

de Jonge MJ, Punt CJ, Sparreboom A, Planting AS, Peters ME, van De Schraaf J, Jackman A, Smith R, de Mulder PH, Verweij J. de Jonge MJ, et al. Among authors: verweij j. J Clin Oncol. 2002 Apr 1;20(7):1923-31. doi: 10.1200/JCO.2002.07.057. J Clin Oncol. 2002. PMID: 11919253 Clinical Trial.

6

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Among authors: verweij j. Clin Cancer Res. 2002 Apr;8(4):1237-41. Clin Cancer Res. 2002. PMID: 11948138 Clinical Trial.

7

Modulation of irinotecan metabolism by ketoconazole.

Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Kehrer DF, et al. Among authors: verweij j. J Clin Oncol. 2002 Jul 15;20(14):3122-9. doi: 10.1200/JCO.2002.08.177. J Clin Oncol. 2002. PMID: 12118026 Clinical Trial.

8

Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel.

Loos WJ, Szebeni J, ten Tije AJ, Verweij J, van Zomeren DM, Chung KN, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Anticancer Drugs. 2002 Aug;13(7):767-75. doi: 10.1097/00001813-200208000-00012. Anticancer Drugs. 2002. PMID: 12187334

9

Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies.

Sparreboom A, Wolff AC, Verweij J, Zabelina Y, van Zomeren DM, McIntire GL, Swindell CS, Donehower RC, Baker SD. Sparreboom A, et al. Among authors: verweij j. Clin Cancer Res. 2003 Jan;9(1):151-9. Clin Cancer Res. 2003. PMID: 12538463

10

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: verweij j. Anticancer Drugs. 2003 Mar;14(3):227-32. doi: 10.1097/00001813-200303000-00006. Anticancer Drugs. 2003. PMID: 12634617 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

927 results

Search Page

Filters